Skip to main content
. Author manuscript; available in PMC: 2015 Jul 21.
Published in final edited form as: Clin Lipidol. 2011;6(1):9–20. doi: 10.2217/clp.10.84

Table 4.

Effect of fenofibrate treatment on progression of diabetic microvascular disease in FIELD and ACCORD-Lipid.

Study Microvascular
outcomes		 Placebo
group,
n (%)		 Fenofibrate
group,
n (%)		 Percentage
change
(p-value)		 Ref.
FIELD Albuminuria progression 539(11) 466(9.5) −13.6 [28]
FIELD Albuminuria regression 400(8.2) 462 (9.4) +14.6(0.0022)† [28]
FIELD Retinopathy (laser
treatment)		 238 (4.9) 164(3.4) −31.1 (0.0002) [50]
ACCORD Microalbuminuria
(post-randomization)		 1137(41.6) 1050(38.2) −8.1 (0.01) [4]
ACCORD Macroalbuminuria
(post-randomization)		 337(12.3) 289(10.5) −14.6(0.03) [4]
ACCORD Diabetic retinopathy
progression‡ 		80(10.2) 52(6.5) −36.3(0.006) [51]

In both FIELD and ACCORD-Lipid, fenofibrate reduced progression of diabetic retinopathy and nephropathy.

†

Combined end point of participants regressing or not progressing with fenofibrate therapy

‡

Combined end point of progression of retinopathy on funduscopic examination and laser photocoagulation.